Cargando…

Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency

Background. Influenza prophylaxis with the use of quadrivalent vaccines (QIV) is increasingly being introduced into healthcare practice. Methods. In total, 32 healthy adults and 6 patients with common variable immunodeficiency (CVID) received adjuvant QIV during 2018–2019 influenza season. Depending...

Descripción completa

Detalles Bibliográficos
Autores principales: Kostinov, Mikhail P., Latysheva, Elena A., Kostinova, Aristitsa M., Akhmatova, Nelly K., Latysheva, Tatyana V., Vlasenko, Anna E., Dagil, Yulia A., Khromova, Ekaterina A., Polichshuk, Valentina B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712402/
https://www.ncbi.nlm.nih.gov/pubmed/33147763
http://dx.doi.org/10.3390/vaccines8040640
_version_ 1783618367248138240
author Kostinov, Mikhail P.
Latysheva, Elena A.
Kostinova, Aristitsa M.
Akhmatova, Nelly K.
Latysheva, Tatyana V.
Vlasenko, Anna E.
Dagil, Yulia A.
Khromova, Ekaterina A.
Polichshuk, Valentina B.
author_facet Kostinov, Mikhail P.
Latysheva, Elena A.
Kostinova, Aristitsa M.
Akhmatova, Nelly K.
Latysheva, Tatyana V.
Vlasenko, Anna E.
Dagil, Yulia A.
Khromova, Ekaterina A.
Polichshuk, Valentina B.
author_sort Kostinov, Mikhail P.
collection PubMed
description Background. Influenza prophylaxis with the use of quadrivalent vaccines (QIV) is increasingly being introduced into healthcare practice. Methods. In total, 32 healthy adults and 6 patients with common variable immunodeficiency (CVID) received adjuvant QIV during 2018–2019 influenza season. Depending on initial antibody titers, healthy volunteers were divided into seronegative (≤1:20) and seropositive (≥1:40). To evaluate immunogenicity hemagglutination inhibition assay was used. Results. All participants completed the study without developing serious post-vaccination reactions. Analysis of antibody titer 3 weeks after immunization in healthy participants showed that seroprotection, seroconversion levels, GMR and GMT for strains A/H1N1, A/H3N2 and B/Colorado, B/Phuket among initially seronegative and seropositive participants meet the criterion of CHMP effectiveness. CVID patients showed increase in post-vaccination antibody titer without reaching conditionally protective antibody levels. Conclusion. Adjuvant QIV promotes formation of specific immunity to vaccine strains, regardless of antibodies’ presence or absence before. In CVID patients search of new regimens should be continued.
format Online
Article
Text
id pubmed-7712402
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77124022020-12-04 Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency Kostinov, Mikhail P. Latysheva, Elena A. Kostinova, Aristitsa M. Akhmatova, Nelly K. Latysheva, Tatyana V. Vlasenko, Anna E. Dagil, Yulia A. Khromova, Ekaterina A. Polichshuk, Valentina B. Vaccines (Basel) Article Background. Influenza prophylaxis with the use of quadrivalent vaccines (QIV) is increasingly being introduced into healthcare practice. Methods. In total, 32 healthy adults and 6 patients with common variable immunodeficiency (CVID) received adjuvant QIV during 2018–2019 influenza season. Depending on initial antibody titers, healthy volunteers were divided into seronegative (≤1:20) and seropositive (≥1:40). To evaluate immunogenicity hemagglutination inhibition assay was used. Results. All participants completed the study without developing serious post-vaccination reactions. Analysis of antibody titer 3 weeks after immunization in healthy participants showed that seroprotection, seroconversion levels, GMR and GMT for strains A/H1N1, A/H3N2 and B/Colorado, B/Phuket among initially seronegative and seropositive participants meet the criterion of CHMP effectiveness. CVID patients showed increase in post-vaccination antibody titer without reaching conditionally protective antibody levels. Conclusion. Adjuvant QIV promotes formation of specific immunity to vaccine strains, regardless of antibodies’ presence or absence before. In CVID patients search of new regimens should be continued. MDPI 2020-11-02 /pmc/articles/PMC7712402/ /pubmed/33147763 http://dx.doi.org/10.3390/vaccines8040640 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kostinov, Mikhail P.
Latysheva, Elena A.
Kostinova, Aristitsa M.
Akhmatova, Nelly K.
Latysheva, Tatyana V.
Vlasenko, Anna E.
Dagil, Yulia A.
Khromova, Ekaterina A.
Polichshuk, Valentina B.
Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency
title Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency
title_full Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency
title_fullStr Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency
title_full_unstemmed Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency
title_short Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency
title_sort immunogenicity and safety of the quadrivalent adjuvant subunit influenza vaccine in seropositive and seronegative healthy people and patients with common variable immunodeficiency
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712402/
https://www.ncbi.nlm.nih.gov/pubmed/33147763
http://dx.doi.org/10.3390/vaccines8040640
work_keys_str_mv AT kostinovmikhailp immunogenicityandsafetyofthequadrivalentadjuvantsubunitinfluenzavaccineinseropositiveandseronegativehealthypeopleandpatientswithcommonvariableimmunodeficiency
AT latyshevaelenaa immunogenicityandsafetyofthequadrivalentadjuvantsubunitinfluenzavaccineinseropositiveandseronegativehealthypeopleandpatientswithcommonvariableimmunodeficiency
AT kostinovaaristitsam immunogenicityandsafetyofthequadrivalentadjuvantsubunitinfluenzavaccineinseropositiveandseronegativehealthypeopleandpatientswithcommonvariableimmunodeficiency
AT akhmatovanellyk immunogenicityandsafetyofthequadrivalentadjuvantsubunitinfluenzavaccineinseropositiveandseronegativehealthypeopleandpatientswithcommonvariableimmunodeficiency
AT latyshevatatyanav immunogenicityandsafetyofthequadrivalentadjuvantsubunitinfluenzavaccineinseropositiveandseronegativehealthypeopleandpatientswithcommonvariableimmunodeficiency
AT vlasenkoannae immunogenicityandsafetyofthequadrivalentadjuvantsubunitinfluenzavaccineinseropositiveandseronegativehealthypeopleandpatientswithcommonvariableimmunodeficiency
AT dagilyuliaa immunogenicityandsafetyofthequadrivalentadjuvantsubunitinfluenzavaccineinseropositiveandseronegativehealthypeopleandpatientswithcommonvariableimmunodeficiency
AT khromovaekaterinaa immunogenicityandsafetyofthequadrivalentadjuvantsubunitinfluenzavaccineinseropositiveandseronegativehealthypeopleandpatientswithcommonvariableimmunodeficiency
AT polichshukvalentinab immunogenicityandsafetyofthequadrivalentadjuvantsubunitinfluenzavaccineinseropositiveandseronegativehealthypeopleandpatientswithcommonvariableimmunodeficiency